HSBC reaffirms buy rating for JD Health International
Published
The major bank HSBC has reaffirmed its buy recommendation for the shares of JD Health International. The financial platform MarketScreener reported this. The assessment shows that the bank's analysts still have a positive view of the company.
JD Health International is an online health platform from China and belongs to the technology group JD.com. The company offers, among other things, the sale of medicines, online consultations with doctors and other digital health services.
A buy recommendation means that financial analysts expect the price of a share to be able to rise in the future. However, the report contains no information about a specific price target or about the reasons HSBC gives for its assessment.
For investors in Germany, the news is mainly of interest in connection with the stock market. However, analysts' assessments are no guarantee of future price developments. Anyone who wants to invest in shares should therefore inform themselves thoroughly before making a decision.
Sources: MarketScreener Deutschland
More Germany news
- Most Germans back development aid, but doubts about funds remain
- Money worries linked to depression, German study finds
- Germany has more children's doctors, fewer patients each
- Berlin records eight diphtheria cases, most since 2001
- Germany Shore trailer shows alleged housemate incident
- BioNTech: Analysts lower price target but stay optimistic
- Japan and Germany: New call for joint energy research
- HCLTech and Cohere bring sovereign AI to Germany and Canada